Several cryptocurrency companies turned to public markets this year, encouraged by the government’s increasingly supportive stance toward digital assets. Among them, Grayscale Investments recently announced plans for an initial public offering. Founded in 2013, the fintech had around $35 billion in assets under management as of September 2025.
The Offering
Last month, the Connecticut-based company filed a registration statement with the Securities and Exchange Commission to list its shares on the New York Stock Exchange under the symbol GRAY. The management is yet to disclose details like the number of shares being offered and the offer price. The group of underwriters managing the offering is led by Morgan Stanley, Bank of America Securities, Jefferies, and Cantor.
Grayscale intends to use proceeds from the offering to purchase membership interests of Grayscale Operating LLC from the latter’s pre-IPO members at a price for each unit equal to the initial public offering price of the company’s stock, after underwriting discounts and commissions.
Grayscale Investments is one of the leading digital asset-focused investment platforms. The company’s products operate within established regulatory frameworks and are backed by institutional-grade partners, including custodians and auditors. Earlier this year, it launched the first diversified digital asset ETP encompassing multiple tokens, beyond Bitcoin and Ethereum.
Financials
For the nine months ended September 2025, Grayscale reported revenues of $318.67 million, compared to $397.87 million in the corresponding period of 2024. Net income for the nine months declined to $203.27 million from $223.69 million in the prior-year period. Cash flow from operations was $179.30 for the period, down 20% year-over-year.
Most Popular
AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts' expectations. Adjusted
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases. In an email interview with AlphaStreet, CEO Dr.
Lamb Weston (LW) is set to report Q2 2026 earnings next week, here’s what to look for
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose over 1% on Thursday. The stock has gained 4% over the past three months. The French fry giant is slated to